← Back

Generate Biomedicines, Inc. Common Stock

Generate Biomedicines, Inc. is a biotechnology company that applies machine learning to drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product candidates include GB-0895, an investigational long-acting anti-TSLP monoclonal antibody for severe asthma intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. The company also develops the Generate Platform, a therapeutic area and protein modality agnostic system that integrates computational innovation with scalable biohardware. Formerly known as Generate Biologics, Inc., it changed its name to Generate Biomedicines, Inc. in February 2020, was incorporated in 2018, and is based in Somerville, Massachusetts.

Price · split & dividend adjusted
News & notes moving GENB
Biotech & Genomic Medicine▲3

Nvidia Discloses $10.4 Million Stake in AI Biotech Generate Biomedicines

Nvidia has disclosed a $10.4 million investment in Generate Biomedicines, a small biotech company using AI and machine learning to accelerate drug development. The stake, revealed in a May 13F filing, consists of over 833,000 shares and aligns with CEO Jensen Huang's view that AI's most profound impact will be in life sciences. Nvidia is also collaborating with Eli Lilly on a five-year, up to $1 billion AI co-innovation lab to expedite drug research. Generate Biomedicines' lead candidate GB-0895, a potential asthma treatment, is currently in Phase 3 trials. The investment could serve as a proof point for Nvidia's chips in healthcare applications beyond chatbots.
GENB ▲LLY ▲NVDA ▲
Biotech & Genomic Medicine ▲Artificial Intelligence
About megatrends
Biotech & Genomic Medicine › AI Drug Discovery ▲Capital
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
Artificial Intelligence › AI Applications & Copilots Technology
GENB · Capital · Positive Nvidia's $10.4 million stake signals confidence and provides capital to Generate Biomedicines.
Generate Biomedicines · Capital · Positive Nvidia's $10.4 million stake signals confidence and provides capital to Generate Biomedicines.
LLY · Demand · Positive Eli Lilly is collaborating with Nvidia on a $1B AI co-innovation lab, indicating strong demand for Nvidia's chips in pharma
NVDA · Demand · Positive Nvidia's investment in Generate Biomedicines and collaboration with Eli Lilly highlight growing demand for its AI chips in life sciences.
Read original ↗
The Motley Fool·85dRead more →
Biotech & Genomic Medicine▲2

Cathie Wood Buys Three IPO Stocks on Monday

Cathie Wood added to three recently public stocks in her Ark Invest ETFs on Monday. She increased positions in Space Exploration Technologies, Generate Biomedicines, and Bullish, all of which went public within the past year. SpaceX, which went public almost a month ago, is set to join the Nasdaq-100 index on Tuesday, potentially driving passive buying. Generate Biomedicines, a clinical-stage generative biology company, is trading above its February IPO price of $16 and has Nvidia as an investor. Bullish, a digital currency exchange and infrastructure provider, has seen its shares fall 72% since going public last summer amid a crypto downturn, though it recently announced a $4.2 billion deal for Equiniti.
BLSH ▼GENB ▲SPCX ▲
Biotech & Genomic Medicine Digital Finance & Tokenization Space Economy
About megatrends
Biotech & Genomic Medicine › AI Drug Discovery Capital
Digital Finance & Tokenization › Crypto Exchanges, Custody & Digital-Asset Infrastructure Competition
Space Economy › Launch Services & Propulsion Capital
BLSH · Demand · Negative Shares down 72% since IPO amid crypto downturn, though recent $4.2B deal for Equiniti may offset.
BLSH · Capital · Negative Shares have fallen 72% since IPO due to crypto downturn, though recent $4.2B Equiniti deal may offset.
GENB · Capital · Positive Trading above IPO price of $16, with Nvidia as investor; Cathie Wood buying adds positive sentiment.
SPCX · Capital · Positive Set to join Nasdaq-100 index, likely driving passive buying.
Generate Biomedicines · Capital · Positive Trading above IPO price of $16, with Nvidia as investor; Cathie Wood buying adds positive sentiment.
Read original ↗
The Motley Fool·89dRead more →
© 2026 MarketDXAsset